| Discoid Lupus Erythematosus |
ChiCTR-TRC-11001195: An evaluation on the efficacy and safety of tacrolimus 0.03% ointment in the treatment of labial lesions of chronic discoid lupus erythematosus and oral lichen planu: a randomized, positive controlled, parallel clinical trial |
|
|
| Completed | 4 | 60 | | Triamcinolone Acetonide Acetate Ointment the first week three times aday; the seconed week two times a day; the third week one times a day ;Tacrolimus 0.03% ointment, the first week three times aday; the seconed week two times a day; the third week one times a day | West China College of Stomatology, Sichuan University; West China College of Stomatology, Sichuan University, Self-financing | chronic discoid lupus erythematosus and oral lichen planus. | | | | |
2007-004635-29: Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions |
|
|
| | 3 | 36 | Europe | ASF-1096 Cream 0.25%, ASF-1096 Cream 0.5%, ASF-1096 Cream 1.0%, | Astion Pharma A/S | Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study. | | | | |
2006-001062-17: Efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with newly developed discoid lupus erythymatosus (DLE) lesions. A multi centre clinical phase 2, placebo controlled and double blind proof of concept study. |
|
|
| | 2 | 20 | Europe | ASF-1096 cream 0.5%, | Astion Danmark A/S | Male or female patients with a clinical diagnosis of either Discoid Lupus Erythmatosus or Systemic Lupus Erythmatosus and at least one newly developed, sharply demarcated DLE lesion. | | 07/07 | | |
2021-004648-27: A Study of Enpatoran in Patients With Systemic Lupus Erythematosus andCutaneous Lupus Erythematosus Un estudio de enpatoran en pacientes con lupus eritematoso sistémico y lupus eritematoso cutáneo |
|
|
| Not yet recruiting | 2 | 532 | Europe, RoW | Enpatoran 25mg, M5049, Film-coated tablet | Merck Healthcare KGaA, Merck Healthcare KGaA | Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) Lupus eritematoso sistémico (LES) y Lupus eritematoso cutáneo (LEC), Systemic lupus erythematosus (SLE) and cutaneous lupuserythematosus (CLE) Lupus eritematoso sistémico (LES) y Lupus eritematoso cutáneo (LEC), Diseases [C] - Immune System Diseases [C20] | | | | |
2022-000831-21: A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus. |
|
|
| Ongoing | 2 | 99 | Europe | daxdilimab, HZN-7734, Solution for injection | Horizon Therapeutics Ireland DAC, Horizon Therapeutics Ireland DAC | Discoid Lupus Erythematosus, Lupus skin disease, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT06261021: Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects With Discoid Lupus Erythematosus |
|
|
| Recruiting | 2 | 20 | Canada | Ruxolitinib 1.5% cream, Application without occlusion in Area 1, Application under occlusion at night in Area 2, Application under occlusion at night in Area 1, Application without occlusion in Area 2 | Innovaderm Research Inc. | Discoid Lupus Erythematosus | 02/25 | 02/25 | | |
| Recruiting | 2 | 99 | Europe, Canada, US, RoW | Placebo/Daxdilimab, Daxdilimab, HZN-7734 | Amgen, Horizon Therapeutics Ireland DAC | Discoid Lupus Erythematosus | 07/24 | 12/24 | | |
NCT04908280: Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus |
|
|
| Completed | 2 | 10 | US | Ruxolitinib | University of Rochester, Incyte Corporation | Discoid Lupus Erythematosus | 03/24 | 03/24 | | |
| Recruiting | 2 | 532 | Europe, Japan, US, RoW | M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
NCT04857034 / 2020-000071-21: A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) |
|
|
| Active, not recruiting | 2 | 75 | Europe, US, RoW | Deucravacitinib, Placebo | Bristol-Myers Squibb, Bristol-Myers Squibb International Corporation | Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous | 07/24 | 08/24 | | |
|
NCT06013995: A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus |
|
|
| Recruiting | 1 | 60 | Europe, US, RoW | BMS-986326, Placebo for BMS-986326 | Bristol-Myers Squibb | Lupus | 11/25 | 11/25 | | |
| Not yet recruiting | N/A | 64 | | Oral hydroxychloroquine + oral DHA ;Oral hydroxychloroquine + oral placebo | North Hospital of Huashan Hospital, Fudan University; North Hospital of Huashan Hospital, Fudan University, Shanghai Shenkang Hospital Development Center | Lupus Erythematosus | | | | |